HCV-associated Marginal Zone Lymphoma · Post-DAA active surveillance for HCV-MZL (after SVR12)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-DAA-OBSERVATION-HCV-MZL`

ID	`IND-HCV-MZL-POST-DAA-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-HCV-MZL`
Sources	`SRC-EASL-HCV-2023` `SRC-ESMO-LYMPHOMA-2025`

Notes

Post-DAA active surveillance pathway. line_of_therapy: 1 reflects continuation of antiviral 1L. Engine activates this after SVR12 confirmed and prior to immunochemotherapy decision. Reassess at 3, 6, 12 months. CR/PR → continue surveillance; SD/PD → route to BR per IND-HCV-MZL-1L-BR-AGGRESSIVE.

Used By

Actionability

BMA-HCV-RNA-MONITORING-DAA-RESPONSE - Quantitative HCV RNA monitoring during direct-acting antiviral (DAA) therapy: pretreatmen...

Algorithms

ALGO-HCV-MZL-2L - ALGO-HCV-MZL-2L

Indication

IND-CHRONIC-HCV-PREVENTION-DAA - IND-CHRONIC-HCV-PREVENTION-DAA